ReviewDiabetic medicine : a journal of the British Diabetic Association2021
An overview of COVID-19 in people with diabetes: Pathophysiology and considerations in the inpatient setting.
Review in Diabetic medicine : a journal of the British Diabetic Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Pre-existing diabetic retinopathy as a prognostic factor for COVID-19 outcomes amongst people with diabetes: A systematic review.Diabetes research and clinical practice · 2022Pooled it
- Unraveling the Mystery: COVID-19 and Diabetic Complications - A Journey from Pathophysiology to Treatment.Current diabetes reviews · 2026Review
- Role of the receptor for advanced glycation end products in the severity of SARS-CoV-2 infection in diabetic patients.Diabetology international · 2024Review
- Unveiling risk factors for post-COVID-19 syndrome development in people with type 2 diabetes.Frontiers in endocrinology · 2024Article
- Article
- A Novel Algorithm for the Management of Inpatient COVID-19 Glucocorticoid-Induced Hyperglycemia.Clinical diabetes : a publication of the American Diabetes Association · 2023Article
- Review
- Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients.iScience · 2022Article
- Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations.Diabetology & metabolic syndrome · 2022Review
- The COVID-19 Patient in the Surgical Intensive Care Unit.The Surgical clinics of North America · 2022Review
- COVID-19 and diabetes-Two giants colliding: From pathophysiology to management.Frontiers in endocrinology · 2022Review
- Stress Hyperglycemia, Diabetes Mellitus and COVID-19 Infection: Risk Factors, Clinical Outcomes and Post-Discharge Implications.Frontiers in clinical diabetes and healthcare · 2022Review
- Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis.Diabetology international · 2021Article
- The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?Cardiovascular diabetology · 2021Article
- Unemployment Syndrome during COVID-19: A Comparison of Three Population Groups.International journal of environmental research and public health · 2021Article
- Optimization in the Context of COVID-19 Prediction and Control: A Literature Review.IEEE access : practical innovations, open solutions · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe coronavirus disease (COVID-19) pandemic has continued to have a devastating impact on health worldwide. There has been a rapid evolution of evidence, establishing an increased risk of morbidity and mortality associated with diabetes and concurrent COVID-19. The objective of this review is to explore the current evidence for inpatient assessment and management of diabetes during the COVID-19 pandemic and highlight areas requiring further exploration.
methodsA literature search of databases was conducted to November 2020 using variations on keywords SARS-CoV-2, COVID-19, SARS, MERS and diabetes. Information relating to the impact of diabetes on severity of COVID-19 infection, the impact of COVID-19 infection on diabetes management and diabetes-related complications was integrated to create a narrative review. DISCUSSION: People with diabetes and COVID-19 are at an increased risk of morbidity and mortality. It is important that people with both known and previously unrecognised diabetes and COVID-19 be promptly identified and assessed during acute illness, with close monitoring for clinical deterioration or complications. People with diabetes may require titration or alteration of their glycaemic management due to the potential for worse outcomes with hyperglycaemia and COVID-19 infection. Comprehensive discharge planning is vital to optimise ongoing glycaemic management.
conclusionFurther understanding of the risk of adverse outcomes and optimisation of glycaemic management for people with diabetes during COVID-19 is required to improve outcomes. Increased glucose and ketone monitoring, substitution of insulin for some oral anti-hyperglycaemic medications and careful monitoring for complications of diabetes such as diabetic ketoacidosis should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.